- This is the Company's second granted patent for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company recently entered into a Clinical Trial ...

Please provide your email address to receive an email when new articles are posted on . The FDA has cleared Brella, a noninvasive, targeted alkali thermolysis product that treats primary axillary ...

NASHVILLE, Tenn., March 18, 2023 /PRNewswire/ -- Candesant Biomedical ("Candesant"), a private medical device company focused on the development and commercialization of non-invasive treatments for ...

Daily treatment with sofpironium bromide gel was generally well-tolerated over 48 weeks of treatment Efficacy assessments showed a clinically meaningful and sustained improvement in sweat severity ...

QBREXZA is the first and only FDA-approved, once-daily, topical prescription treatment indicated for people 9 years of age and older with primary axillary hyperhidrosis, also known as excessive ...

The US Food and Drug Administration (FDA) today cleared the first patch to reduce excessive underarm sweating for adults with primary axillary hyperhidrosis. The single-use, disposable, ...

The FDA approved sofpironium topical gel 12.45% (Sofdra) for primary axillary hyperhidrosis, according to a statement from Botanix Pharmaceuticals. The approval stipulates use in adults and children 9 ...

Sofpironium bromide indirectly reduces the rate of sweating by preventing the stimulation of acetylcholine receptors that are located on sweat glands. The Food and Drug Administration (FDA) has ...

- This is the Company's first patent issued for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -- The Company is currently discussing partnership ...